CorMedix (CRMD) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CorMedix (CRMD) has outperformed Valneva (VALN) over the past year, losing 34.4% versus a loss of 44.9%. Over five years, CRMD leads with a +47.1% price change compared with -79.1% for VALN. CorMedix is the larger company by market cap ($565.1 million vs $536.2 million), about 1.1 times the size.
On valuation, Valneva trades at a lower forward P/E (4.8x vs 20.7x for CorMedix).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | VALN |
|---|---|---|
| Share price | $7.25 | $5.66 |
| Market cap | $565.10M | $536.23M |
| 1-day change | -0.41% | -3.66% |
| YTD return | -37.40% | -33.45% |
| 1-year return | -34.36% | -44.88% |
| 5-year return | +47.07% | -79.07% |
| P/E ratio (TTM) | 3.54 | — |
| Forward P/E | 20.71 | 4.75 |
| EPS (TTM) | $2.05 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.02 | $12.18 |
| 52-week low | $6.13 | $4.75 |
| Distance from 52-week high | -44.32% | -53.57% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +111.45% | +116.62% |
| Average volume | 1.06M | 78.15K |
| Shares outstanding | 77.94M | 94.82M |
| Employees | 191 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRMD has outperformed VALN by 10.5 percentage points over the past year.
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
CRMD vs VALN FAQ
Which is bigger, CorMedix or Valneva?
CorMedix (CRMD) is larger, with a market capitalization of $565.10M compared with $536.23M for Valneva (VALN).
Which stock has performed better over the past year, CRMD or VALN?
CRMD returned -34.36% over the past 12 months, compared with -44.88% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Valneva in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for CorMedix and Biotechnology: Biological Products (No Diagnostic Substances) for Valneva.